Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02271945 · ClinicalTrials.gov registry record · Phase 1
Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapies in Subjects With Aggressive B-cell Lymphomas
A Phase 1 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT02271945 is a Phase 1 study that has completed, run by MedImmune. The registered enrollment target is 10 participants.
The verdict
NCT02271945, a Phase 1 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
This is a Phase 1b/2 open-label study to evaluate the safety/efficacy of MEDI-551 + MEDI0680 in participants with relapsed or refractory aggressive B-cell lymphomas who have failed 1-2 prior lines of therapy.
Interventions
- DRUG MEDI-551 12 mg/kg
- DRUG MEDI0680 2.5 mg/kg
- DRUG MEDI0680 10 mg/kg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2014-12-01 |
| Est. Completion | 2016-05-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02271945
The ClinicalTrials.gov registry entry for NCT02271945 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which MEDI-551 12 mg/kg is the first listed.
NCT02271945 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02271945 about?
NCT02271945 is a clinical study titled "Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapies in Subjects With Aggressive B-cell Lymphomas". This is a Phase 1b/2 open-label study to evaluate the safety/efficacy of MEDI-551 + MEDI0680 in participants with relapsed or refractory aggressive B-cell lymphomas who have failed 1-2 prior lines of therapy.
What is the current status of trial NCT02271945?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2014-12-01. Estimated completion is 2016-05-24.
What interventions are being tested in trial NCT02271945?
The interventions under investigation include: MEDI-551 12 mg/kg (DRUG), MEDI0680 2.5 mg/kg (DRUG), MEDI0680 10 mg/kg (DRUG).
Who is sponsoring clinical trial NCT02271945?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.